|
1
|
Seidman AD, Berry D, Cirrincione C, et al:
Randomized phase III trial of weekly compared with every-3-weeks
paclitaxel for metastatic breast cancer, with trastuzumab for all
HER-2 overexpressors and random assignment to trastuzumab or not in
HER-2 nonoverexpressors: final results of Cancer and Leukemia Group
B protocol 9840. J Clin Oncol. 26:1642–1649. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Weiss RB, Donehower RC, Wiernik PH, et al:
Hypersensitivity reactions from taxol. J Clin Oncol. 8:1263–1268.
1990.PubMed/NCBI
|
|
3
|
Mielke S, Sparreboom A and Mross K:
Peripheral neuropathy: a persisting challenge in paclitaxel-based
regimes. Eur J Cancer. 42:24–30. 2006. View Article : Google Scholar
|
|
4
|
Taxol® (paclitaxel) injection
[packaging insert]. Princeton, NJ, USA: Bristol-Myers Squibb
Company; 2007
|
|
5
|
Gradishar JW, Tjulandin S, Davidson N, et
al: Phase III trial of nanoparticle albumin-bound paclitaxel
compared with polyethylated castor oil-based paclitaxel in women
with breast cancer. J Clin Oncol. 23:7794–7803. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Eisenhauer EA, Therasse P, Bogaerts J, et
al: New response evaluation criteria in solid tumours: revised
RECIST guideline (version 1.1). Eur J Cancer. 45:228–247. 2009.
View Article : Google Scholar
|
|
7
|
Japan Clinical Oncology Group. Common
Terminology Criteria for Adverse Events version 4.0. http://www.jcog.jp/doctor/tool/CTCAEv4J_20140920.pdf.
Accessed December 10, 2014
|
|
8
|
Abraxane® for Injectable
Suspension (nab-paclitaxel) [packaging insert]. Summit, NJ, USA:
Celegene Corporation; 2013
|
|
9
|
Nabholtz JM, Gelmon K, Bontenbal M, et al:
Multicenter, randomized comparative study of two doses of
paclitaxel in patients with metastatic breast cancer. J Clin Oncol.
14:1858–1867. 1996.PubMed/NCBI
|
|
10
|
Jones SE, Erban J, Overmoyer B, et al:
Randomized phase III study of docetaxel compared with paclitaxel in
metastatic breast cancer. J Clin Oncol. 23:5542–5551. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Albain KS, Nag SM, Calderillo-Ruiz G, et
al: Gemcitabine plus Paclitaxel versus Paclitaxel monotherapy in
patients with metastatic breast cancer and prior anthracycline
treatment. J Clin Oncol. 26:3950–3957. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Harris LN, Broadwater G, Lin NU, et al:
Molecular subtypes of breast cancer in relation to paclitaxel
response and outcomes in women with metastatic disease: results
from CALGB 9342. Breast Cancer Res. 8:R662006. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Rowinsky EK and Donehower RC: Paclitaxel
(Taxol). N Engl J Med. 332:1004–1014. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Swain SM and Arezzo JC: Neuropathy
associated with microtubule inhibitors: diagnosis, incidence, and
management. Clin Adv Hematol Oncol. 6:455–467. 2008.PubMed/NCBI
|
|
15
|
Ibrahim NK, Samuels B, Page R, et al:
Nanoparticle paclitaxel (ABI-007) in metastatic breast cancer
(MBC): efficacy and evidence of dose-dependent activity in two
multicenter phase II studies. Proc Am Soc Clin Oncol.
21:2092002.
|
|
16
|
Hilpert F, Stähle A, Tomé O, et al;
Arbeitsgemeinschaft Gynäkologische Onkologoie (AGO) Ovarian Cancer
Study Group. Neuroprotection with amifostine in the first-line
treatment of advanced ovarian cancer with
carboplatin/paclitaxel-based chemotherapy - a double-blind,
placebo-controlled randomized phase II study from the
Arbeitsgemeinschaft Gynäkologische Onkologie (AGO) Ovarian Cancer
Study Group. Support Care Cancer. 13:797–805. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
De Vos FY, Bos AM, Schaapveld M, et al: A
randomized phase II study of paclitaxel with carboplatin +/−
amifostine as first line treatment in advanced ovarian carcinoma.
Gynecol Oncol. 97:60–67. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Lorusso D, Ferrandina G, Greggi S, et al;
Multicenter Italian Trials in Ovarian Cancer Investigators. Phase
III multicenter randomized trial of amifostine as cytoprotectant in
first-line chemotherapy in ovarian cancer patients. Ann Oncol.
14:1086–1093. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Sevelda P, Sevelda U, Denison U and Kaider
A; Austrian Society of Gynecologic Oncology. Cytoprotection of
amifostine (A) in ovarian cancer patients receiving
paclitaxel/carboplatin (PC) first line chemotherapy in a
multicenter phase III trial. J Clin Oncol, 2004 ASCO Annual Meeting
Proc (Post-Meeting Edition). (July 15 Suppl)22:50212004.
|
|
20
|
Leong SS, Tan EH, Fong KW, et al:
Randomized double-blind trial of combined modality treatment with
or without amifostine in unresectable stage III non-small-cell lung
cancer. J Clin Oncol. 21:1767–1774. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Gelmon K, Eisenhauer E, Bryce C, et al:
Randomized phase II study of high-dose paclitaxel with or without
amifostine in patients with metastatic breast cancer. J Clin Oncol.
17:3038–3047. 1999.PubMed/NCBI
|
|
22
|
Jacobson SD, Loprinzi CL, Sloan JA, et al:
Glutamine does not prevent paclitaxel-associated myalgias and
arthralgias. J Support Oncol. 1:274–278. 2003.
|
|
23
|
Argyriou AA, Chroni E, Koutras A, et al:
Vitamin E for prophylaxis against chemotherapy-induced neuropathy:
a randomized controlled trial. Neurology. 64:26–31. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Center for Cancer Control and Information
Services. National Estimates of Cancer Incidence Based on Cancer
Registries in Japan (1975–2010). http://ganjoho.jp/pro/statistics/en/table_download.html#02.
Accessed December 10, 2014
|
